Podcast appearances and mentions of rahul banerjee

  • 16PODCASTS
  • 41EPISODES
  • 38mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • May 23, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about rahul banerjee

Latest podcast episodes about rahul banerjee

The HemOnc Pulse
Inside the War on Myeloid Malignancies: Early Clues & Bold Innovations

The HemOnc Pulse

Play Episode Listen Later May 23, 2025 20:32


In this episode of HemOnc Pulse, host Rahul Banerjee, MD, FACP of Fred Hutch Cancer Center is joined by myeloid malignancy expert Uma Borate, MBBS of The Ohio State University, for a high-impact discussion on one of hematology's hottest frontiers: early detection. As aggressive diseases like AML and MDS continue to outpace traditional diagnostics, this conversation dives into why spotting these cancers sooner isn't just helpful—it's lifesaving.  

The HemOnc Pulse
Redirected Strategy: Tal and TEC in the Myeloma Mix

The HemOnc Pulse

Play Episode Listen Later May 2, 2025 16:51


In this episode of The HemOnc Pulse, Rahul Banerjee, MD of Fred Hutchinson Cancer Center is joined by Gurbakhash Kaur, MD of Mount Sinai for an in-depth discussion of the RedirecTT-1 trial, recently published in the New England Journal of Medicine. The conversation explores the evolving role of bispecific antibodies in multiple myeloma, with a focus on the combination of talquetamab (Tal) and teclistamab (TEC). Drs. Banerjee and Kaur unpack the trial's rationale, design, and real-world implications for patients with relapsed or refractory disease. Tune in to hear expert perspectives on unmet needs in late-line myeloma care, emerging toxicity profiles, and the future of dual-targeted immunotherapy.

Oncology Data Advisor
Additional Advances in Relapsed/Refractory Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP

Oncology Data Advisor

Play Episode Listen Later Apr 4, 2025 48:31


The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical. In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health's Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease. Don't miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice. Click below to access these valuable resources: Accredited CME/NCPD Podcast: bit.ly/3B4gSB1 Position Statement in Blood Cancer Journal: www.nature.com/articles/s41408-024-01129-0 Live Task Force Recording: www.youtube.com/live/TILCPB6w3Ig?…=1Z8m4dA2qwLJd6rN

Oncology Peer Review On-The-Go
S1 Ep151: Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Oncology Peer Review On-The-Go

Play Episode Listen Later Mar 3, 2025 56:47


CancerNetwork®, in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT), organized an X Space hosted by Rahul Banerjee, MD, FACP, an assistant Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center in Seattle, Washington, and Shernan Holtan, MD, the chief of Blood and Marrow Transplantation and professor of Medicine at Roswell Park Comprehensive Cancer Center.  The conversation took place during the 2025 Tandem Meeting and highlighted many significant presentations and posters on CAR T-cell therapies and transplantation, Banerjee's and Holtan's respective areas of expertise. The following trials were discussed: LBA1 - Phase II Multicenter Trial of Idecabtagene Vicleucel (Ide-cel) Followed By Lenalidomide Maintenance for Multiple Myeloma Patients with Sub-Optimal Response after an Upfront Autologous Hematopoietic Cell Transplantation: Top Line Results from the BMT CTN 1902 Clinical Trial1 “This [study] is nice because it merges 2 worlds. It's like a tandem—but not really a tandem—because you're not doing 2 transplants back-to-back. You're doing a transplant followed by CAR T-cell therapy,” said Banerjee. Abstract 50 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium2 “In a relatively small cohort, [investigators] found no difference in 9-month survival whether someone got their [CAR T cells] in second-line therapy vs third-line therapy from a statistical perspective. If you look at the curves, it looks like there is a potential benefit to second-line therapy, but there was not enough statistical power to determine a difference,” said Holtan. Poster 340 - CD83 Expression By Human Breast Cancer Mediates Effective Killing By CAR T3 “If there's a way to do [the therapy] armored and have a paracrine delivered in real time—and not given to the whole body—[so] the patient [would] have all the adverse effects and cytokine release syndrome release on their own…that would be awesome,” stated Banerjee.  Poster 317 - Risk Factors for Immune Effector Cell-Associated Enterocolitis (IEC-colitis) in Patients with Relapsed Myeloma Treated with Ciltacabtagene Autoleucel (cilta-cel)4 “From the best that we can tell, ironically, corticosteroids aren't the fix that we want them to be [for immune effector cell-associated colitis]…We were like ‘Diarrhea, whatever. Let's give some steroids and treat it like gut graft-versus-host-disease,' but these patients [didn't] respond as well [to that],” said Banerjee. Poster 572 - Post-CAR-T Driving Restrictions Appear Unnecessary after Week 4: Data from the US Multiple Myeloma Immunotherapy Consortium5 “Patients and their caregivers [who have] put their life aside for 4 weeks just to get through CAR T-cell therapy and the Risk Evaluation and Mitigation Strategies requirements are now being told ‘You're free to go, but you can't drive for 4 weeks, which means you can't get your own groceries or…go to doctor's appointments by yourself.' Basically, we argue…that this [requirement] is not evidence-based,” stated Banerjee.  Presentation 58 - Physical Function Measures Identify Non-Hodgkin Lymphoma Patients at High Risk of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and 1-Year Mortality after Chimeric Antigen Receptor T (CAR-T) Cell Therapy6 “This [presentation] highlights that even within a high [CAR-HEMATOTOX group], those patients were at extraordinarily high risk of not benefitting from CAR T-cell therapy, and these tests are so simple to do. It's going to be interesting to see if others can reproduce this,” said Holtan. Poster 618 - Comparison of Outcomes after Hematopoietic STEM Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Patients Older or Younger THAN 65 YEARS Old. a Retrospective Analysis of the Latin America Registry7 “My personal hope for this space is that our field can come up with more novel conditioning regimens such that we can ablate the marrow without causing those gastrointestinal toxicities or other organ toxicities [while] doing that so effectively that we don't even need maintenance therapies for a lot of conditions,” stated Holtan. Presentation 39 - Determinants of Immune Suppression Discontinuation in the Modern Era: A CIBMTR Analysis of 18,642 Subjects8 “I'm going to make a provocative prediction for the next paper [approximately 10 years from now]. I predict that steroids won't be the first-line therapy for acute or chronic graft-versus-host-disease,” Holtan said. Poster 516 - Patient Experiences with Chronic Graft-Versus-Host Disease and Its Treatment in the United States: A Retrospective Social Media Listening Study9 “We can still work together to make life as good as we possibly can [for patients], to improve physical function, to take away some of this mental distress, and then work together for advocacy too. [We can] help with peer support, help with resources, and help relieve some of that misunderstanding in the community,” stated Holtan. References 1.        Garfall AL, Pasquini MC, Bai L, et al. Phase II multicenter trial of idecabtagene vicleucel (ide-cel) followed by lenalidomide maintenance for multiple myeloma patients with sub-optimal response after an upfront autologous hematopoietic cell transplantation: top line results from the BMT CTN 1902 clinical trial. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract LBA-1. 2.        Rojek AE, Ahmed N, Gomez-Llobell M, et al. CAR T cell therapy in early relapsed/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Abstract 50. 3.        Betts BC, Davilla ML, Linden AM, et al. CD83 expression by human breast cancer mediates effective killing by CAR T. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 340. 4.        Chang Lim KJ, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 317. 5.        Banerjee R, Richards A, Khouri J, et al. Post-CAR-T driving restrictions appear unnecessary after week 4: data from the US multiple myeloma immunotherapy consortium. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 572. 6.        Herr M, McCarthy P, Jacobsen H, et al. Physical function measures identify non-Hodgkin lymphoma patients at high risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and 1-year mortality after chimeric antigen receptor T (CAR-T) cell therapy. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 58. 7.        Duarte FB, Garcia YDO, Funke VAM, et al. Comparison of outcomes after hematopoietic STEM cell transplantation (HCT) for myelodysplastic syndrome (MDS) patients older or younger THAN 65 YEARS Old. A retrospective analysis of the Latin America registry. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 618. 8.        Pidala J, DeFlilipp Z, DeVos J, et al. Determinants of immune suppression discontinuation in the modern era: a CIBMTR analysis of 18,642 subjects. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Presentation ID 39. 9.        Cowden M, Derrien-Connors C, Holtan S, et al. Patient experiences with chronic graft-versus-host disease and its treatment in the United States: A retrospective social media listening study. Presented at: 2025 Transplant and Cellular Therapy Meetings; February 12-15, 2025; Honolulu, HI. Poster ID 516.

Couchonomics with Arjun
Ep 95. Transforming Access And Trading Bonds To A New Era With Rahul Banerjee

Couchonomics with Arjun

Play Episode Listen Later Sep 24, 2024 51:49


In this episode of Couchonomics with Arjun, we're joined by Rahul Banerjee, Founder & CEO of Bondblox, to explore the future of bond trading. Rahul shares how Bondblox is transforming access to bonds, opening up opportunities for retail investors in a market traditionally controlled by institutions.Arjun and Rahul discuss the rapid growth of the bond market, particularly in Asia, and how technology is playing a key role in bridging the gap between institutional and individual investors. If you're curious about the bond market's impact on your wealth or interested in the latest financial innovations, this conversation is one you won't want to miss!Tune in to gain a fresh perspective on bonds and finance in the modern era.Our website

Oncology Data Advisor
Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma

Oncology Data Advisor

Play Episode Listen Later Sep 10, 2024 33:18


Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma. To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm

ASTCT Talks
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

ASTCT Talks

Play Episode Listen Later Sep 3, 2024 18:21


In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2 Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.” References FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379

Oncology Peer Review On-The-Go
S1 Ep125: Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

Oncology Peer Review On-The-Go

Play Episode Listen Later Sep 2, 2024 18:21


In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and a professor of medicine at Harvard Medical School. Banerjee and Raje spoke in the context of prior advisories from the FDA on the potential development of secondary T-cell malignancies in patients who receive CAR T-cell therapy for hematologic cancers. Specifically, the agency required a boxed warning for secondary T-cell malignancy risks for BCMA- or CD19-targeting therapies in April 2024.1 The conversation also touched upon reports of secondary malignancies in cases and trials such as CARTITUDE-1 (NCT04181827), in which second primary cancers were highlighted in 9 patients who received treatment with ciltacabtagene autoleucel (Carvykti).2  Considering these reports and warnings, Banerjee and Raje emphasized shared treatment decision-making with patients after assessing the risks and benefits of CAR T-cell therapy compared with other agents like bispecific antibodies. They also reviewed optimal strategies for monitoring and referring patients based on the incidence of certain toxicities. “[Treatment with] CAR T cells requires planning, and we need to have good control of the disease. We need to have 4 to 6 weeks of a lead time to get these effective treatments to our patients, so early referral is a good idea,” Raje said. “[For example], if you see chronic diarrhea in someone that is way out of the window of what you would expect, referring back to the CAR T-cell center is important so that we don't miss some of these toxicities.”  References 1. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. News release. FDA. April 18, 2024. Accessed August 22, 2024. https://tinyurl.com/5n8pm5ca  2. San-Miguel J, Dhakal B, Yong K, et al. CIlta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379 

Oncology Data Advisor
Additional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP

Oncology Data Advisor

Play Episode Listen Later May 3, 2024 5:54


Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health's online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma Live or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma

Oncology Data Advisor
Multiple Myeloma Awareness Month 2024: What Patients Need to Know

Oncology Data Advisor

Play Episode Listen Later Apr 3, 2024 58:07


For Multiple Myeloma Awareness Month this March, Oncology Data Advisor hosted a live panel discussion geared towards patients living with multiple myeloma. Dr. Rahul Banerjee, Dr. Alankrita Taneja, Dr. Richa Thakur, and Dr. Gurbakhash Kaur helped put the myriad of new developments in multiple myeloma treatment into perspective for patients and answered questions from the audience regarding current and future treatment strategies for multiple myeloma.

Oncology Data Advisor
Rare Disease Day 2024 With Rahul Banerjee, Matthew Hadfield, Joseph Kalis, and Nagashree Seetharamu

Oncology Data Advisor

Play Episode Listen Later Mar 18, 2024 43:43


On Rare Disease Day on February 29, members of the Oncology Data Advisor Editorial Board and Fellows Forum hosted a live panel discussion focused on the rare diseases that they treat, including tireless efforts underway to develop novel treatment strategies, enhance quality of life, and improve outcomes for patients.

Oncology Data Advisor
Improving QOL in Multiple Myeloma With Bortezomib Dose Reduction: Rahul Banerjee and Gurbakhash Kaur

Oncology Data Advisor

Play Episode Listen Later Jan 8, 2024 8:16


At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!

Oncology Data Advisor
Venetoclax for Multiple Myeloma in the Post-CANOVA Era: Rahul Banerjee, MD, FACP, and Andrew Yee, MD

Oncology Data Advisor

Play Episode Listen Later Nov 15, 2023 20:22


At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.

ASTCT Talks
Beyond BCMA: Exploring Talquetamab in Myeloma Therapy

ASTCT Talks

Play Episode Listen Later Nov 15, 2023 17:52


In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab. Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapies and the potential of GPRC5D-targeted therapy in improving outcomes. Tune in to learn about the evolving landscape of myeloma treatment beyond BCMA. About Dr. Rahul Banerjee, MD, FACP Dr. Rahul Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington. His clinical interests are in multiple myeloma and CAR-T therapy. He has authored over 60 peer-reviewed publications with a research emphasis on reducing toxicities and improving the patient experience during treatment for multiple myeloma. About Dr. Amrita Krishnan, MD Dr. Amrita Krishnan, MD (@DoctorAKrishnan) directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, seeking to make gains in one of the most rapidly changing areas in cancer research. A key member of the City of Hope team since 1996, Dr. Krishnan trained at The University of Rochester, Beth Israel Hospital, Fred Hutchinson Research Cancer Center and Dana Farber Cancer Institute. She serves as a steering committee member on the Multiple Myeloma Research Foundation and the North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee and is the Co-Chair of several of the largest myeloma transplant trials in the U.S. Her research interests are in development of new drugs for relapsed myeloma and understanding mechanisms of disease resistance.

Oncology Data Advisor
Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023: Rahul Banerjee and Shonali Midha

Oncology Data Advisor

Play Episode Listen Later Nov 7, 2023 18:36


At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.

Oncology Data Advisor
Twice Weekly, Biweekly, Somewhere in Between? Dosing in Myeloma: Rahul Banerjee and Gurbakhash Kaur

Oncology Data Advisor

Play Episode Listen Later Oct 23, 2023 17:14


In honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.

ASTCT Talks
Monitoring After CAR-T Therapy for Multiple Myeloma: The APP Perspective

ASTCT Talks

Play Episode Listen Later Aug 18, 2023 25:39


In this latest episode of ASTCT Talks, Rahul Banerjee interviews Josh Epworth, a lead nurse practitioner in the plasma cell disorders clinic at the Fred Hutchinson Cancer Center. They delve into the topic of monitoring after CAR-T therapy for multiple myeloma. Mr. Epworth shares insights from his experience in the outpatient setting, discussing issues like hypogammaglobulinemia, immune cell functionality, and infections that may arise after CAR-T treatment. They also touch on monitoring for cytomegalovirus (CMV) and other respiratory viruses, as well as the importance of developing close relationships with local healthcare providers to ensure patients receive timely care. About Josh Epworth, MSN, ARNP Josh Epworth is a Nurse Practitioner at the Fred Hutchinson Cancer Center (FHCC) and is a Teaching Associate at the University of Washington School of Medicine. He is board-certified in Adult/Gerontology medicine and specializes in the treatment of multiple myeloma. As a staff member of FHCC's multiple myeloma team, Mr. Epworth is involved in disease treatment, symptom management, patient education and clinical trials. About Dr. Rahul Banerjee, MD, FACP Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced fellowship in BMT/CAR-T therapy at the University of California San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience. This episode was sponsored by Janssen Oncology and Legend Biotech.

ASTCT Talks
Treating Cytopenias After CAR T-cell Therapy

ASTCT Talks

Play Episode Listen Later May 5, 2023 22:12


In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Tania Jain, MBBS. They dive into "How I Treat Cytopenias after CAR T-cell Therapy,” a paper published by Dr. Jain and co-authors (Timothy S. Olson, MD, PhD and Frederick Locke, MD) in Blood in February 2023. They discuss why cytopenias occur after CAR-T therapy, how to evaluate cytopenias after CAR-T therapy, who best to manage cytopenias after CAR-T and more. About Dr. Rahul Banerjee, MD, FACP Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced fellowship in BMT/CAR-T therapy at the University of California San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience. About Dr. Tania Jain, MBBS Dr. Jain, MBBS, (@TaniaJain11) is a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins. Her academic focus is cellular therapy and transplantation in the treatment of high-risk hematological malignancies especially myeloproliferative neoplasms. Her primary research focus is to develop strategies to improve outcomes and prevent relapse of hematological malignancies following allogeneic stem cell transplantation. She also serves as the Director of the Immune Effector Cell (IEC) Therapy at Johns Hopkins, where they are currently expanding their CAR T program to help patients with advanced hematological malignancies. Her academic interest in this space lies in developing novel IEC strategies and studying aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients.

ASTCT Talks
Bispecific Antibodies in Myeloma: The Who, What, When, and Where

ASTCT Talks

Play Episode Listen Later Apr 18, 2023 18:38


In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Urvi A. Shah, MD, to discuss CAR-T vs bsAbs among academic audiences, bispecific antibodies (in particular commercially available teclistamab), future cycles of teclistamab, infections in published trials of bsAbs in myeloma and more. About Dr. Rahul Banerjee, MD, FACP Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced fellowship in BMT/CAR-T therapy at the University of California San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience. About Dr. Urvi A. Shah, MD Dr. Urvi Shah, MD, (@UrviShahMD) is an Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK) and Assistant Professor of Medicine at Weill Cornell Medicine. She completed fellowships in hematology/oncology at Montefiore Medical Center, and in cancer immunotherapy by MSK and the Parker Institute for Cancer Immunotherapy in New York. She is board certified in Internal Medicine, Hematology and Medical Oncology.  Her clinical practice includes all plasma cell disorders and her research interests include immune therapies and modifiable risk factors (diet, metabolism, and the microbiome). She opened the first pilot nutrition trial in plasma cell disorders to date (NUTRIVENTION; NCT04920084) in 2021 that completed enrollment. She has 3 other NUTRIVENTION/immune therapy investigator-initiated trials (NCT05640843, NCT04497961, NCT04174196) currently enrolling. Dr. Shah has been supported by career development awards from the National Cancer Institute Paul Calabresi K12, International Myeloma Society and American Society of Hematology Scholar Award.

Oncology Data Advisor
Understanding Clonal Hematopoiesis With Rahul Banerjee, Jeremy Meier, and Samuel Rubinstein

Oncology Data Advisor

Play Episode Listen Later Nov 14, 2022 25:45


Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.

Oncology Data Advisor
Blood Cancer Awareness Month: Exploring Patient-Reported Outcomes: Rahul Banerjee and Ajay Major

Oncology Data Advisor

Play Episode Listen Later Oct 7, 2022 31:32


Recently, Dr. Rahul Banerjee, Assistant Professor at the University of Washington and Editorial Board member for Oncology Data Advisor, spoke with Dr. Ajay Major, Assistant Professor at the University of Colorado, in a live interview discussion in honor of Blood Cancer Awareness Month. Dr. Banerjee and Dr. Major engaged in a riveting conversation about the role of patient-reported outcomes (PROs) in lymphoma and myeloma, including how to interpret them and how to include them when designing research.

Oncology Data Advisor
The Future of MRD in Multiple Myeloma Treatment Decision Making

Oncology Data Advisor

Play Episode Listen Later Aug 29, 2022 35:00


In this interview, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee speaks with Dr. Ben Derman, Assistant Professor of Medicine at the University of Chicago, about his research regarding measurable residual disease (MRD) detection in multiple myeloma and its potential role in guiding treatment decisions.

Winning the War on Cancer (Video)
Cancer: What Are the Newest Developments?

Winning the War on Cancer (Video)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Mini Medical School for the Public (Audio)
Cancer: What Are the Newest Developments?

Mini Medical School for the Public (Audio)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Health and Medicine (Video)
Cancer: What Are the Newest Developments?

Health and Medicine (Video)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Oncology Data Advisor
Addressing Racial Disparities in Multiple Myeloma Treatment Outcomes

Oncology Data Advisor

Play Episode Listen Later Jun 17, 2022 27:16


Research has shown that Black American patients with multiple myeloma experience significant disparities in treatment patterns and outcomes compared with White patients. In this interview, Oncology Data Advisor editorial board member Dr. Rahul Banerjee speaks with Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas Medical School and a leading researcher in the field of multiple myeloma treatment disparities.

Breast Cancer (Video)
Cancer: What Are the Newest Developments?

Breast Cancer (Video)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

University of California Audio Podcasts (Audio)
Cancer: What Are the Newest Developments?

University of California Audio Podcasts (Audio)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Health and Medicine (Audio)
Cancer: What Are the Newest Developments?

Health and Medicine (Audio)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Breast Cancer (Audio)
Cancer: What Are the Newest Developments?

Breast Cancer (Audio)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Winning the War on Cancer (Audio)
Cancer: What Are the Newest Developments?

Winning the War on Cancer (Audio)

Play Episode Listen Later Jun 17, 2022 77:50


There are many new developments in cancer care. This program focuses on three exciting areas of cancer diagnosis and treatment. Dr. Hope Rugo, a leader in breast cancer research, leads a discussion on tumor DNA with Mark Magbanua, Ph.D., novel imagining techniques with Dr. Courtney Lawhn Heath,and CAR T-cell therapy with Dr. Rahul Banerjee. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 37847]

Oncology Data Advisor
Can Digital Health Tools Improve Quality of Life in Multiple Myeloma?

Oncology Data Advisor

Play Episode Listen Later Apr 28, 2022 19:53


In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Neha Korde of Memorial Sloan Kettering Cancer Center about the potential of digital health tools to improve quality of life for patients with multiple myeloma.

Oncology Data Advisor
Considering VTE Risk Factors and Prophylaxis in Myeloma: Rajshekhar Chakraborty and Rahul Banerjee

Oncology Data Advisor

Play Episode Listen Later Apr 11, 2022 19:56


In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor Editorial Board, speaks with Dr. Rajshekhar Chakraborty about risk factors for the development of venous thromboembolism (VTE) in patients with multiple myeloma and the considerations for thromboprophylaxis during their treatment.

Oncology Data Advisor
Can Diet and Nutrition Impact Multiple Myeloma Outcomes? Urvi Shah and Rahul Banerjee

Oncology Data Advisor

Play Episode Listen Later Apr 6, 2022 23:45


In honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee, a Clinical Fellow in Medicine at the University of California, San Francisco, and member of the Oncology Data Advisor editorial board, speaks with Dr. Urvi Shah about the importance of ensuring proper diet and nutrition, as well as the impact of the microbiome, for patients with multiple myeloma.

ASTCT Talks
Titans of Transplant: Dr. Krishna Komanduri

ASTCT Talks

Play Episode Listen Later Apr 4, 2022 41:14


In the next installment of ASTCT's Titans of Transplant series, Dr. Rahul Banerjee, Advanced Fellow, BMT/CAR-T Therapy, with the Division of Hematology/Oncology in the Department of Medicine at the University of California San Francisco, speaks with Dr. Krishna Komanduri, who is a professor of medicine at the University of Miami and the Kalish Family Chair and Chief of Division of Transplantation and Cellular Therapy at Sylvester Comprehensive Cancer Center. The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.

Oncology Data Advisor
Advocating for Patients in Multiple Myeloma Clinical Trials: Manni Mohyuddin and Rahul Banerjee

Oncology Data Advisor

Play Episode Listen Later Mar 24, 2022 24:38


In this interview in honor of Multiple Myeloma Awareness Month, Dr. Rahul Banerjee speaks with Dr. Manni Mohyuddin about the importance of designing clinically relevant end points for clinical trials in multiple myeloma.

Oncology Data Advisor
Can Digital Life Coaching Improve Quality of Life in Transplant? Rahul Banerjee and Kelly Brassil

Oncology Data Advisor

Play Episode Listen Later Feb 17, 2022 27:24


Dr. Rahul Banerjee and Dr. Kelly Brassil discuss the design of an ongoing phase 2 trial investigating digital life coaching and its implications for improving the quality of life of patients undergoing ASCT for multiple myeloma.

ASTCT Talks
A Deep Dive On Early Time-to-Toci

ASTCT Talks

Play Episode Listen Later Jul 29, 2021 25:18


Join Dr. Rahul Banerjee, Advanced Fellow of BMT / CAR T Therapy in the Department of Medicine at the University of California San Francisco, and Dr. Nina Shah, Associate Professor in the Department of Medicine at UC San Francisco, as they discuss their paper “Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.” The paper was co-authored by Drs. Shah and Banerjee, along with several colleagues, and was published in ASTCT's Transplantation and Cellular Therapy Journal in March.

Plenary Session
4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul Banerjee

Plenary Session

Play Episode Listen Later Jul 8, 2021 91:43


We sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions. What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Where Dreams Come From
Rahul Banerjee (English)

Where Dreams Come From

Play Episode Play 32 sec Highlight Listen Later May 19, 2021 24:49 Transcription Available


Trained as an engineer at the Indian Institutes of Technology or IIT, my guest Rahul Banerjee gave up the securities of an Indian middle class life to serve his country. He threw his lot behind the indigenous Bhil tribal folk in central India. Along the way, he has completed a PhD, become an Ashoka Fellow and completed numerous research projects for organizations internationally. But the central focus, as Banerjee explains, has been a lifelong process of unlearning and then organizing to secure constitutional rights for the poorest of the poor in India. This conversation is a snapshot of that journey.Support the show (https://www.paypal.com/biz/fund?id=HGJKF8TKYSKRN)

The Brand Called You
Rahul Banerjee, Water Resource Management Specialist & Adivasi Development and Natural Resource Management Specialist

The Brand Called You

Play Episode Listen Later Feb 23, 2021 24:35


Follow us on Facebook - http://facebook.com/followtbcy/ Twitter - http://twitter.com/followtbcy/ Instagram - http://instagram.com/followtbcy/ YouTube - http://youtube.com/followtbcy --- Support this podcast: https://anchor.fm/tbcy/support